Shopping Cart 0
Cart Subtotal
USD 0

Recordati SpA (REC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Recordati SpA (Recordati), a subsidiary of Fimei SpA is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, dermatology, central nervous system disorders, musculo-skeletal disorders and analgesia and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over the counter (OTC) and non-prescription pharmaceuticals, antiinfectives and others. It also produces pharmaceutical chemicals, such as active pharmaceutical ingredients (APIs) and intermediates. Recordati sells its pharmaceuticals directly in the countries where it is present and through licensees in other places. Recordati is headquartered in Milano, Italy.

Recordati SpA (REC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Recordati SpA, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Recordati Acquires Rights to Cystagon from Mylan 13

Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14

Recordati Acquires Rights for Seloken from Astrazeneca 15

Recordati Rare Diseases Acquires North American Rights to Cystadane 16

Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For USD 100 Million 17

Recordati Completes Acquisition Of Portfolio Of Products From Akvion For USD 87 Million 19

Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21

Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22

Private Equity 23

CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 23

Partnerships 25

Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25

Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26

Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27

Licensing Agreements 28

Recordati Enters into Licensing Agreement with MimeTech 28

Recordati Enters into Licensing Agreement with Meyer Hospital 29

Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30

Recordati Enters into Licensing Agreement with Assistance Publique-Hopitaux de Paris 31

Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 32

Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 33

Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34

Plethora Enters into Licensing Agreement with Recordati for PSD502 36

Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38

Acquisition 39

Recordati Acquires Pro Farma for USD16.2 Million 39

Recordati Acquires Italchimici for up to USD145 Million 40

Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41

Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For USD 122.5 Million 43

Recordati Completes Acquisition Of Farma-Projekt For USD 21 Million 45

Recordati SpA-Key Competitors 46

Recordati SpA-Key Employees 47

Recordati SpA-Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Recent Developments 51

Financial Announcements 51

Oct 30, 2018: Recordati announces sales and margin growth in the first nine months 2018. revenues +5.1%, ebitda +11.1%, operating income +9.6%, net income +8.2%. interim dividend EUR 0.45 (+7.1%). 51

Jul 26, 2018: Recordati announces sales and margin growth in the first half 2018. Revenues +6.9%, operating income +14.1%, net income +11.7% 52

May 08, 2018: Recordati Announces Sales and Margin Growth in the First Quarter 2018 53

Mar 15, 2018: Recordati: Board Approves The 201 7 Accounts 54

Feb 08, 2018: Recordati: Preliminary 2017 Results Confirm Continued Growth of Sales and Profitability. Sales +11.6%, Operating Income +24.1%, Net Income +21.6% 57

Oct 26, 2017: Recordati: Very Good Results in the First Nine Months 2017. Continued Growth in Sales +11.8%, Operating Income +21.8%, Net Income +20.6%. Interim Dividend EUR 0.42 (+20%) 58

Jul 27, 2017: Recordati: Very Good Results In The First Half 2017. Continued Growth In Sales +10.7%, Operating Income +19.4%, Net Income +19.8% 60

May 04, 2017: Recordati: Excellent Results in the First Quarter 2017. Continued Growth in Sales +13.1%, Operating Income +19.0%, Net Income +19.9% 62

Mar 01, 2017: Recordati: Board Approves The 2016 Accounts. Sales EUR 1,153.9 Million (+10.1%), Operating Income EUR 327.4 Million (+17.6%) And Net Income EUR 237.4 Million (+19.4%). 2016 Dividend EUR 0.70 (+16.7%) 63

Feb 09, 2017: Recordati: Preliminary 2016 Results Confirm Continued Growth Of Revenues And Profitability 66

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Recordati SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Recordati SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Recordati SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Recordati SpA, Deals By Therapy Area, 2012 to YTD 2018 9

Recordati SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Recordati Acquires Rights to Cystagon from Mylan 13

Recordati Acquires Consumer Health Brands from Bayer Consumer Care 14

Recordati Acquires Rights for Seloken from Astrazeneca 15

Recordati Rare Diseases Acquires North American Rights to Cystadane 16

Recordati Completes Acquisition Of Portfolio Of Products From Lundbeck For USD 100 Million 17

Recordati Completes Acquisition Of Portfolio Of Products From Akvion For USD 87 Million 19

Recordati Acquires Dentosan Line Of Oral Care Products From Cilag 21

Recordati Acquires Six Over The Counter Products From Cilag And McNeil 22

CVC Fund to Acquire Majority Stake in Recordati for USD3.5 Billion 23

Recordati and Plethora Enter into Co-Development Agreement with Pharmaserve for PSD502 25

Prasco Labs Enters into Distribution Agreement with Recordati Rare Diseases 26

Ony Enters Into Co-Promotion Agreement With Recordati Rare Diseases For NeoProfen 27

Recordati Enters into Licensing Agreement with MimeTech 28

Recordati Enters into Licensing Agreement with Meyer Hospital 29

Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 30

Recordati Enters into Licensing Agreement with Assistance Publique-Hopitaux de Paris 31

Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 32

Erytech Pharma enters into Licensing Agreement with Orphan Europe for Graspa 33

Recordati Amends Licensing Agreement with Plethora Solutions for Fortacin 34

Plethora Enters into Licensing Agreement with Recordati for PSD502 36

Gebro Pharma Enters Into Licensing Agreement With Recordati For Kentera 38

Recordati Acquires Pro Farma for USD16.2 Million 39

Recordati Acquires Italchimici for up to USD145 Million 40

Recordati Completes Acquisition of 90% Interest in Opalia Pharma for USD37.6 Million 41

Recordati Completes Acquisition Of Laboratorios Casen Fleet From C.B. Fleet For USD 122.5 Million 43

Recordati Completes Acquisition Of Farma-Projekt For USD 21 Million 45

Recordati SpA, Key Competitors 46

Recordati SpA, Key Employees 47

Recordati SpA, Subsidiaries 48

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Recordati SpA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.